ERBB2 and breast carcinoma: Furthermore, the American Society of Clinical Oncology (ASCO) released a rapid guideline recommendation update to support the use of adjuvant olaparib in patients with early-stage, high-risk HER2- breast cancer and a gBRCA mutation [16].